1st Quarter - Amendment

THE UNITED STATES PHARMACOPEIAL CONVENTION for THE UNITED STATES PHARMACOPEIAL CONVENTION

Firm
Client
Income
—
Expenses
$130,000
Expense method
B: tax-exempt organisations, Internal Revenue Code section 6033(b)(8)

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report Apr 20, 2026 $110,000 Replaced
1st Quarter - Amendment (this page) Jul 20, 2026 $130,000 Yes

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

S. 1784 - Mapping America's Pharmaceutical Supply (MAPS) Act; H.R. 4191: Provisions regarding supply chain security and resilience and drug shortages. S. 3788 - Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings Act (CLEAR LABELS) Act: Provisions regarding drug labeling.

LobbyistCovered position, as disclosed
TIMOTHY J CASEY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 1784 (119th), H.R. 4191 (119th), S. 3788 (119th)

Budget/Appropriations BUD

Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027: Provisions related to Administration for Strategic Preparedness and Response (ASPR) mapping. FY 2027 Commerce, Justice, Science, and Related Agencies Appropriations: Provisions related to 3D-printing. FY 2027 State-Foreign Operations Appropriations: Provisions related to pharmaceutical supply chain resilience.

LobbyistCovered position, as disclosed
TIMOTHY J CASEY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.